Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M. Levitz D, et al. Among authors: shastri a. Clin Cancer Res. 2023 Aug 1;29(15):2774-2780. doi: 10.1158/1078-0432.CCR-23-0842. Clin Cancer Res. 2023. PMID: 37341641
High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.
Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A. Goel S, et al. Among authors: shastri a. Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. Leukemia. 2016. PMID: 27125205 No abstract available.
STAT3 inhibition as a therapeutic strategy for leukemia.
Kanna R, Choudhary G, Ramachandra N, Steidl U, Verma A, Shastri A. Kanna R, et al. Among authors: shastri a. Leuk Lymphoma. 2018 Sep;59(9):2068-2074. doi: 10.1080/10428194.2017.1397668. Epub 2017 Nov 22. Leuk Lymphoma. 2018. PMID: 29164994 Review.
Therapeutic targeting of the inflammasome in myeloid malignancies.
Chakraborty S, Shapiro LC, de Oliveira S, Rivera-Pena B, Verma A, Shastri A. Chakraborty S, et al. Among authors: shastri a. Blood Cancer J. 2021 Sep 14;11(9):152. doi: 10.1038/s41408-021-00547-8. Blood Cancer J. 2021. PMID: 34521810 Free PMC article. Review.
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Rahmani NE, Ramachandra N, Sahu S, Gitego N, Lopez A, Pradhan K, Bhagat TD, Gordon-Mitchell S, Pena BR, Kazemi M, Rao K, Giricz O, Maqbool SB, Olea R, Zhao Y, Zhang J, Dolatshad H, Tittrea V, Tatwavedi D, Singh S, Lee J, Sun T, Steidl U, Shastri A, Inoue D, Abdel-Wahab O, Pellagatti A, Gavathiotis E, Boultwood J, Verma A. Rahmani NE, et al. Among authors: shastri a. Blood Cancer J. 2021 Sep 21;11(9):157. doi: 10.1038/s41408-021-00541-0. Blood Cancer J. 2021. PMID: 34548471 Free PMC article.
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
Gonzalez-Lugo JD, Kambhampati S, Yacoub A, Donnellan WB, Berdeja J, Bhagat P, Fehn K, Remy C, Jasra S, Kazemi M, Pradhan K, Kim M, Mantzaris I, Sica RA, Shah N, Goldfinger M, Kornblum N, Gritsman K, Braunschweig I, Steidl U, Will B, Shastri A, Verma A. Gonzalez-Lugo JD, et al. Among authors: shastri a. Clin Cancer Res. 2023 Jan 4;29(1):60-66. doi: 10.1158/1078-0432.CCR-22-1457. Clin Cancer Res. 2023. PMID: 36255372 Clinical Trial.
Splicing factor deficits render hematopoietic stem and progenitor cells sensitive to STAT3 inhibition.
Potts KS, Cameron RC, Metidji A, Ghazale N, Wallace L, Leal-Cervantes AI, Palumbo R, Barajas JM, Gupta V, Aluri S, Pradhan K, Myers JA, McKinstry M, Bai X, Choudhary GS, Shastri A, Verma A, Obeng EA, Bowman TV. Potts KS, et al. Among authors: shastri a. Cell Rep. 2022 Dec 13;41(11):111825. doi: 10.1016/j.celrep.2022.111825. Cell Rep. 2022. PMID: 36516770 Free PMC article.
Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma.
Bazarbachi AH, Reef D, Narvel H, Patel R, Al Hamed R, Vikash S, Neupane K, Atalla E, Thakkar A, Rahman S, Shah U, Adrianzen-Herrera D, Quinn R, Zareef S, Rabinovich E, De Castro A, Joseph F, Gillick K, Mustafa J, Khatun F, Lombardo A, Townsend-Nugent L, Abreu M, Chambers N, Elkind R, Shi Y, Wang Y, Derman O, Gritsman K, Steidl U, Goldfinger M, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, Shah N, Cooper D, Verma A, Ye BH, Janakiram M, Sica RA. Bazarbachi AH, et al. Among authors: shastri a. Clin Hematol Int. 2023 Jun;5(2-3):78-91. doi: 10.1007/s44228-023-00032-y. Epub 2023 Mar 15. Clin Hematol Int. 2023. PMID: 36918485 Free PMC article.
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review.
Vegivinti CTR, Keesari PR, Veeraballi S, Martins Maia CMP, Mehta AK, Lavu RR, Thakur RK, Tella SH, Patel R, Kakumani VK, Pulakurthi YS, Aluri S, Aggarwal RK, Ramachandra N, Zhao R, Sahu S, Shastri A, Verma A. Vegivinti CTR, et al. Among authors: shastri a. Exp Hematol Oncol. 2023 Jul 8;12(1):60. doi: 10.1186/s40164-023-00422-1. Exp Hematol Oncol. 2023. PMID: 37422676 Free PMC article. Review.
207 results